Fcγ Receptor Engineered T Cells for Solid Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, including CAR T cells and combinations with antibodies, have been disappointing in treating solid tumors, as they rely on the host T-cell repertoire and have safety concerns.
Innovation Solution
Genetically engineering T cells to express a first polypeptide comprising an Fc receptor common γ chain (FcRγ) and a second polypeptide with an extracellular ligand-binding domain of an Fcγ receptor, allowing for activating signal transmission upon binding of an Fc ligand.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If T cells are genetically engineered to express Fcγ receptors and FcRγ signaling chains, then the killing capability against tumor cells coated with antibodies is enhanced, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The Fcγ receptor is divided into separate functional domains: an extracellular ligand-binding domain (from FcγRI, FcγRII, FcγRIII, or FcγRIV) and an intracellular signaling chain (FcRγ). This segmentation allows independent optimization of binding and signaling functions while simplifying the genetic engineering process compared to introducing complete complex receptor systems.
Solution Approach 2:
The engineered T cells can recognize multiple tumor targets through the Fcγ receptor's ability to bind the Fc portion of various antibodies. This universal mechanism allows a single T cell product to potentially target different tumor antigens depending on the antibody used, reducing the need for multiple specialized T cell products.
2Object-affected harmful factors
If T cells rely on the host T-cell repertoire for tumor recognition, then the safety profile is improved, but the effectiveness against solid tumors is reduced
Solution Approach 1:
The Fcγ receptor acts as an intermediary that bridges the antibody-antigen binding event and T cell activation. Instead of requiring direct T cell receptor recognition of tumor antigens (which is limited by host repertoire), the Fcγ receptor mediates recognition through antibody binding, expanding target recognition capabilities while maintaining T cell-mediated safety mechanisms.
Solution Approach 2:
The T cell is engineered with a composite receptor system combining the Fcγ receptor extracellular domain (for antibody binding) with the FcRγ signaling chain (for T cell activation). This composite structure integrates antibody-based target recognition with T cell-based selective activation, achieving both expanded effectiveness and maintained safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered T cells demonstrate enhanced killing capabilities of tumor cells coated with antibodies, offering a promising approach for treating solid tumors with a higher safety profile.
Implementation Method 1
a second polypeptide comprising an extracellular ligand-binding domain of an Fcγ receptor capable of binding an Fc ligand
Data Source
AI summary
A T cell expressing an FC gamma receptor is provided. Accordingly there is provided a T cell genetically engineered to express a first polypeptide comprising an amino acid sequence of an Fc receptor common γ chain (FcRγ), said amino acid sequence is capable of transmitting an activating signal; and a second polypeptide comprising an extracellular ligand-binding domain of an Fcγ receptor capable of binding an Fc ligand and an amino acid sequence capable of recruiting said first polypeptide such that upon binding of said Fc ligand to said extracellular ligand-binding domain of said Fcγ receptor said activating signal is transmitted.